section name header

Pronunciation ⬇

za-NA-mi-veer

Classifications ⬆ ⬇

Therapeutic Classification: antivirals

Pharmacologic Classification: neuraminidase inhibitors

Indications ⬆ ⬇

REMS


Action ⬆ ⬇

  • Inhibits the enzyme neuraminidase, which may alter virus particle aggregation and release.
Therapeutic effects:
  • Reduced duration or prevention of flu-related symptoms.

Pharmacokinetics ⬆ ⬇

Absorption: 4–17% of inhaled dose is systemically absorbed.

Distribution: Unknown.

Protein Binding: <10%.

Metabolism/Excretion: Mainly excreted by kidneys as unchanged drug; unabsorbed drug is excreted in feces.

Half-Life: 2.5–5.1 hr.

Time/Action Profile ⬆ ⬇

(blood levels)

ROUTEONSETPEAKDURATION
Inhalationrapid1–2 hr12 hr



Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

Neuro: abnormal behavior, agitation, delirium, hallucinations, nightmares, SEIZURES

Resp: bronchospasm

Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS AND ANGIOEDEMA)

Interactions ⬆ ⬇

Drug-drug:

Route/Dosage ⬆ ⬇

Treatment of Influenza

Prophylaxis of Influenza

Availability ⬆ ⬇

Assessment ⬆ ⬇

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆

Relenza